Externautics

Externautics is a biotech company exploiting possibilities for the identification and development of diagnostics for oncology applications.

EXTERNAUTICS is an innovative biotech company established in 2007 to exploit the unique possibilities offered by the Reverse Proteomic YOMICSÂ Platform toward the identification and development of novel diagnostic and therapeutic markers for Oncology applications. The past ten years have seen a tremendous increase in the use of Monoclonal Antibodies for the treatment of cancer diseases. Herceptin and Erbitux are clear examples of the present trends of the cancer clinical therapy to target and kill tumor cells on the basis of specific protein markers present on the tumors. Yet, the frequency of tumor regression is still limited to a very low percentage of the patient population submitted to treatment.